Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yondelis + Caelyx versus Caelyx alone in relapsed ovarian cancer
ACTRN12607000169448Phase 3Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Aug 2005
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Caelyx alone with Caelyx + Yondelis (2 arms). Primary endpoint: Progression-free survival. Started Aug 2005; status: recruiting.
02
Drugs
trabectedinpegylated liposomal doxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12607000169448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000169448.